Introduction
============

Sudden cardiac death is the leading cause of death in the world. Statistics show that in China, the number of sudden cardiac death per year is 544,000 ([@b1-etm-0-0-5325]). Cardiopulmonary resuscitation (CPR) is the most effective way to save the lives of patients. However, CPR still failed to achieve satisfactory results in the treatment of cardiac arrest (CA). The literature reported that 40% of patients undergoing CPR treatment achieved return of spontaneous circulation (ROSC), 10--30% of patients were completely cured and discharged, and the remaining patients died of disease ([@b2-etm-0-0-5325]). However, patients with successful rescue can often have a variety of complications, such as permanent neurological complications, including cognitive disorders and dyskinesia ([@b3-etm-0-0-5325]); post-resuscitation cardiac dysfunction is also an important reason leading to poor prognosis of patients ([@b4-etm-0-0-5325]), it manifests as systemic ischemia and reperfusion syndrome. At the same time, due to the sharp increase of a variety of deregulation cytokines in the blood 3 h after CA, such as endotoxin releasing into the plasma, there will be severe sepsis, leading to tissue damage ([@b5-etm-0-0-5325]--[@b7-etm-0-0-5325]). Therefore, it is of important clinical significance to explore an effective treatment in order to improve the CPR postoperative prognosis.

In this experiment, we selected ulinastatin (UTI). UTI is derived from human urinary protease inhibitors ([@b8-etm-0-0-5325]). It has been proved to have anti-inflammatory, inhibiting neutrophil elastase, inhibiting chemokine release and penetration effects ([@b9-etm-0-0-5325]). In addition, UTI protects mitochondrial function by reducing calcium overload in cells, playing a role in the protection of heart, lung, liver, kidney ischemia-reperfusion injury ([@b10-etm-0-0-5325]). However, few studies have evaluated the effect of UTI on cardiac dysfunction after CPR. In the present study, we adopted continuous renal replacement therapy (CRRT) at the same time, analyzed the role of UTI + CRRT in early CPR, to provide some theoretical basis for clinical treatment and improving the prognosis of CA.

Materials and methods
=====================

### Clinical data

A total of 70 patients who were treated for CPR in Ganzhou People\'s Hospital from October 2016 to March 2017 were selected as the subjects. All patients or their families signed informed consent, all procedures were in accordance with the principles set out in the Helsinki Declaration. A total of 70 patients were randomly divided into control group (n=35, male 18, female 17, mean age: 53.71±5.41 years) and UTI combined with CRRT group (UTI + CRRT, n=35, male 19, female 16, mean age: 54.64±14.72 years). According to the American Heart Association guidelines, CPR was performed, if necessary, chest compression and defibrillation was given in reference to Advanced Cardiac Life Support Protocol. The study was approved by the Ethics Committee of Ganzhou People\'s Hospital.

Successful recovery was defined as patients showing significant pulse and electrocardiography rhythm as well as ventricular tachycardia or fibrillation. In the control group, patients were treated with conventional symptomatic therapy. In the UTI + CRRT group, patients were treated with intravenous injection of UTI immediately after ROSC (Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd., Guangzhou, China; SFDA approval no. H9990134) (300,000 U dissolved in 20 ml NaCl solution), once every 12 h. At the same time, CRRT treatment was performed with Diapact CRRT (B. Braun Melsungen AG, Melsungen, Germany), 3 times for each patient: Once per day for 3 days, 8 h for each treatment. All patients underwent preoperative and post-resuscitation APACHE II scoring by the same physician.

### Sample collection and testing

The whole blood samples of the patients were collected at 4 time points (0, 3, 6 and 12 h) after CPR. After collecting them in the sodium citrate anticoagulant tube, the cells were centrifuged for 5 min at 1,500 × g, then preserved at −80°C immediately. After all the samples were collected, tumor necrosis factor-α (TNF-α), IL-6, malondialdehyde (MDA) and cardiac troponin I (cTnI) were measured in all samples. Blood samples from patients were analyzed for pH, SO~2~, HCO~3~^−^ and lactic acid (LAC) using i-STAT System 300 (Abbott Laboratories Inc., NY, USA). The cTnI concentration was measured using the Abbott AXSYM system. The MDA content was determined by the kit (Sigma; Merck KGaA, Darmstadt, Germany).

### Detection of serum TNF-α and IL-6 by ELISA

The levels of TNF-α and IL-6 in the serum of the patients were determined by the ELISA kit (Abcam, Cambridge, MA, USA). The reaction was carried out according to the kit instructions. The reaction product was measured at 450 nm wavelength and the OD values were measured, the expression was analyzed.

### Detection of toll-like receptor 4 (TLR4) expression by RT-PCR

The lymphocytes in the blood were extracted using the TBD lymphocyte extraction kit (Tiangen Biotech Co., Ltd., Beijing, China), and RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The concentration of extracted RNA was measured using a spectrophotometer, 1 µg of RNA was taken for reverse transcription (Takara Bio, Inc., Otsu, Japan). The mRNA levels of each indicators were determined using SYBR-Green fluorescent reagent (Toyobo Life Science, Osaka, Japan). TLR4 gene primers were synthesized by Sangon Biotech Shanghai Co., Ltd. (Shanghai, China). Sequences: Upstream 5′-CGTCTAGTCTAGAGCATCATC-3′; downstream 5′-GAGAAATGAGGAAGTAAGGG-3′; internal reference GAPDH: Upstream 5′-AGGTCGGTGTGAACGGATTTG-3′; downstream 5′-TGTAGACCATGTAGTTGAGGTCA-3′. The relative expression level of each index is 2-ΔCq \[ΔCq = Cq (target gene) - Cq (GAPDH)\].

### Statistical analysis

The results were analyzed using GraphPad Prism software (Version 5.01; GraphPad Software, Inc., San Diego, Chile). The differences of the indicators between the two groups were compared by independent sample t-test. The expression of each indicator at four time points was measured using the variance analysis of repeated measurements. A P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### The basic physiological variables of the control and the experimental group

There was no significant difference in body temperature, heart rate, mean arterial pressure, cardiac defibrillation and basic life support between the two groups (P\>0.05) ([Table I](#tI-etm-0-0-5325){ref-type="table"}).

### Evaluation of the difference between the biochemical indicators at different time points between the two groups of patients

The levels of pH and SaO~2~ in the two groups were not significantly different at any time point (P\>0.05). Compared with the control group, the levels of HCO~3~^−^ and LAC in the CRRT + UTI group was downregulated significantly at 3 h after ROSC ([Table II](#tII-etm-0-0-5325){ref-type="table"}).

### Serum cTnI and plasma MDA expression

After CPR, the cTnI in the blood of the two groups showed a continuous upward trend, and MDA reached the peak at 3 h of ROSC. Starting from ROSC 3 h, UTI combined with CRRT significantly reduced the expression of cTnI and MDA (P\<0.05) ([Fig. 1](#f1-etm-0-0-5325){ref-type="fig"}).

### RT-PCR detection of TLR4 mRNA levels

The patient\'s TLR4 mRNA expression reached the peak 3 h after the CPR, and then decreased. The expression levels of TLR4 mRNA in the CRRT + UTI group were lower than those in the control group at four time points (0, 3, 9, and ROSC 12 h) (P\<0.05) ([Fig. 2](#f2-etm-0-0-5325){ref-type="fig"}).

### Detection of the expression of IL-6 and TNF-α by ELISA

After CPR, the levels of IL-6 and TNF-α in the blood of the two groups reached the peak at 9 h and 3 h of ROSC, respectively. However, the levels of IL-6 and TNF-α in UTI + CRRT were significantly lower than those in the control group (P\<0.05) ([Fig. 3](#f3-etm-0-0-5325){ref-type="fig"}).

### Average recovery time of consciousness and spontaneous breathing after CPR

The average recovery time of consciousness and spontaneous breathing for the patients in UTI combined with CRRT was significantly shorter than the control group (P\<0.05) ([Table III](#tIII-etm-0-0-5325){ref-type="table"}).

### APACHE II score of two groups

APACHE II scores were assessed by designated physicians before and 24 h after CPR. UTI combined with CRRT significantly reduced APACHE II scores ([Table IV](#tIV-etm-0-0-5325){ref-type="table"}).

Discussion
==========

After CA occurs in patients, it can lead to various pathological situations, such as inflammation, oxidative stress, myocardial damage and heart damage. In the present study, we analyzed multiple biomarkers at multiple time points after CPR treatment, including cTnI, MDA, TLR4, TNF-α, and IL-6. CTnI is a specific marker of myocardial injury ([@b11-etm-0-0-5325]). Early myocardial injury can be detected by serum cTnI levels ([@b12-etm-0-0-5325]). In the present study, serum cTnI was continuously elevated in both groups, but the level of UTI + CRRT was significantly lower than that of the control group. Changes in cTnI suggest that CA will inevitably lead to myocardial injury in patients, but the use of UTI + CRRT can reduce the damage to a certain extent.

It has been shown that oxidative stress is associated with lipid peroxidation and is one of the mechanisms of neuronal injury induced by ischemia-reperfusion ([@b13-etm-0-0-5325],[@b14-etm-0-0-5325]). MDA, as the final product of lipid oxidation, can cause cross-linked polymerization of protein, nucleic acid and other macromolecules, and has cytotoxicity, it is often used as a marker of oxidative stress after ischemia-reperfusion ([@b15-etm-0-0-5325],[@b16-etm-0-0-5325]). In the present study, plasma MDA levels in both groups increased significantly, reached a peak at 3 h after CPR treatment, and combination of UTI + CRRT significantly decreased MDA content, indicating that UTI and CRRT have protective effects on myocardium after CPR.

Organ damage CA after successful CRP is considered to associate with systemic inflammatory response; various cytokines and lipopolysaccharide (LPS) levels have been proved to have risen significantly in patients with successful resuscitation ([@b17-etm-0-0-5325],[@b18-etm-0-0-5325]). TLR4 recognizes LPS, which promotes the production of a variety of inflammatory cytokines (IL-6 and TNF-α), leading to sepsis-like syndrome ([@b19-etm-0-0-5325]). Activated TLR4 promotes nuclear factor expression during cerebral ischemia and hypoxia, and induces the production of cytokines such as TNF-α and IL-6, causing inflammation and nerve damage ([@b20-etm-0-0-5325]). Therefore, we speculate that TLR4 signaling pathway may inhibit the inflammatory response and nerve damage by hypoxic preconditioning, thus protecting brain function. In addition, previous studies have shown that UTI can reduce lung and kidney damage caused by LPS inhibiting the inflammatory response of these organs ([@b21-etm-0-0-5325]). In this study, TLR4 gene was significantly upregulated in both groups after CPR, and TNF-α and IL-6 were also upregulated. UTI combined with CRRT significantly lowered these indicators and shortened the recovery time of consciousness and spontaneous breathing, reduced the APACHE II score.

In conclusion, we found that UTI combined with CRRT can protect against ischemia/reperfusion injury caused by early CPR, and can inhibit the inflammatory response induced by TLR4 after early CPR.

![Serum expression of cTnI and plasma. After CPR, cTnI in the blood of the two groups continued to increase, and MDA peaked at 3 h after ROSC. The expression of cTnI and MDA in UTI + CRRT group was significantly lower than that in control group from ROSC 3 h. UTI + CRRT vs. control group, \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001. cTnI, cardiac troponin I; CPR, cardiopulmonary resuscitation; MDA, malondialdehyde; UTI, ulinastatin; CRRT, continuous renal replacement theraphy; ROSC, return of spontaneous circulation.](etm-14-06-6064-g00){#f1-etm-0-0-5325}

![RT-PCR detection of TLR4 mRNA levels. The patient\'s TLR4 mRNA expression reached the peak 3 h after the CPR, and then decreased. The expression levels of TLR4 mRNA in the CRRT + UTI were lower than those in the control group at four time points (0 h, 3 h, 9 h and ROSC 12 h) (P\<0.05). UTI + CRRT vs. control group, \*P\<0.05, \*\*P\<0.01. RT-PCR, reverse transcription-polymerase chain reaction; TLR4, toll-like receptor 4; CPR, cardiopulmonary resuscitation; CRRT, continuous renal replacement therapy; UTI, ulinastatin; ROSC, return of spontaneous circulation.](etm-14-06-6064-g01){#f2-etm-0-0-5325}

![ELISA detection of IL-6, and TNF-α expression. After CPR, the levels of IL-6 and TNF-α in the blood of the two groups reached the peak at 9 h and 3 h of ROSC, respectively. However, the levels of IL-6 and TNF-α in UTI + CRRT group were significantly lower than those in control group. UTI + CRRT group vs. control group, \*P\<0.05. TNF-α, tumor necrosis factor-α; IL-6, interleukin-6, CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation; UTI, ulinastatin; CRRT, continuous renal replacement theraphy.](etm-14-06-6064-g02){#f3-etm-0-0-5325}

###### 

Baseline physiology and resuscitation related variables (mean ± SD).

  Item                    Control (n=35)   UTI + CRRT (n=35)   t-test   P-value
  ----------------------- ---------------- ------------------- -------- ---------
  Age                     46.54±7.62       48.02±9.33          2.473    0.883
  Sex                                                                   
    Male                  17               19                  3.234    0.673
    Female                18               16                  3.667    0.594
  Body temperature (°C)   37.7±0.4         37.5±0.6            0.968    0.753
  HR (times/min)          263±20           270±22              0.889    0.832
  MAP (mm/Hg)             85±9             87±11               0.802    0.477
  DF (times)              3±1              3±1                 0.661    0.482
  BLS (min)               3.7±2.0          3.6±1.8             0.539    0.724

HR, heart rate; MAP, mean arterial pressure; DF, cardiac defibrillation; BLS, basic life support; SD, standard deviation.

###### 

Comparison of biochemical indicators in two groups (mean ± SD).

                                ROSC                                                                                                                                                                                              
  -------------- -------------- ----------- --------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------- -------- --------
  Control        pH             7.25±0.04   7.26±0.05                                                 7.28±0.07                                                7.25±0.04                                                 1.352    0.236
  (n=35)         SaO~2~ (%)     94±2        94±3                                                      93±4                                                     93±3                                                      1.023    0.991
                 HCO~3~^−^      34±3        30±3                                                      27±4                                                     23±5                                                      0.420    0.621
                 (mmol/l)       7.46±2.15   6.04±2.02                                                 5.53±2.68                                                3.92±2.66                                                 0.524    0.268
                 Lac (mmol/l)                                                                                                                                                                                                     
  CRRT + UTI     pH             7.24±0.04   7.25±0.06                                                 7.26±0.08                                                7.24±0.05                                                 1.0839   0.738
  group (n=35)   SaO~2~ (%)     95±3        94±4                                                      95±4                                                     93±4                                                      0.832    0.651
                 HCO~3~^−^      34±4        25±4^[a](#tfn3-etm-0-0-5325){ref-type="table-fn"}^        19±5^[b](#tfn4-etm-0-0-5325){ref-type="table-fn"}^       17±4^[a](#tfn3-etm-0-0-5325){ref-type="table-fn"}^        7.453    0.0326
                 (mmol/l)       7.51±2.42   4.06±1.83^[a](#tfn3-etm-0-0-5325){ref-type="table-fn"}^   3.08±1.7^[a](#tfn3-etm-0-0-5325){ref-type="table-fn"}^   2.74±1.50^[a](#tfn3-etm-0-0-5325){ref-type="table-fn"}^   6.883    0.0192
                 Lac (mmol/l)                                                                                                                                                                                                     

UTI + CRRT vs. control group

P\<0.05

P\<0.01. ROSC, return of spantaneous circulation; Lac, lactic acid; CRRT, continuous renal replacement theraphy; UTI, ulinastatin; SD, standard deviation.

###### 

The time of recovery of consciousness and spontaneous breathing (h) (mean ± SD).

  Groups       n    Average recovery time of spontaneous breathing         Average recovery time of consciousness                  t-test    P-value
  ------------ ---- ------------------------------------------------------ ------------------------------------------------------- --------- ---------
  Control      35   15±7.2                                                                                                         36±11.2   
  CRRT + UTI   35   33±8.5^[b](#tfn7-etm-0-0-5325){ref-type="table-fn"}^   52±12.5^[a](#tfn6-etm-0-0-5325){ref-type="table-fn"}^   2.604     0.0204

UTI + CRRT vs. control group

P\<0.05

P\<0.01. CRRT, continuous renal replacement theraphy; UTI, ulinastatin; SD, standard deviation.

###### 

APACHE II score (mean ± SD).

               APACHE II score (points)                
  ------------ -------------------------- ------------ ----------------------------------------------------------
  Control      35                         24.41±4.41   21.34±6.23
  UTI + CRRT   35                         24.57±5.34   16.60±8.49^[a](#tfn9-etm-0-0-5325){ref-type="table-fn"}^

UTI + CRRT vs. control group

P\<0.01. CRRT, continuous renal replacement theraphy; UTI, ulinastatin; SD, standard deviation.
